Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. Expand
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease. Expand
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth. Expand
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
- P. Kearney, C. Baigent, J. Godwin, H. Halls, J. Emberson, C. Patrono
- BMJ : British Medical Journal
- 1 June 2006
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess. Expand
Low-dose aspirin for the prevention of atherothrombosis.
- C. Patrono, L. G. García Rodríguez, R. Landolfi, C. Baigent
- The New England journal of medicine
- 1 December 2005
This review considers the role of low-dose aspirin for the prevention of atherothrombosis as well as clinical and epidemiologic studies of aspirin as an antiplatelet agent, with special emphasis on the benefits and risks in different patient populations. Expand
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised…
Alteplase increased the odds of a good stroke outcome, with earlier treatment associated with bigger proportional benefit, and Proportional treatment benefits were similar irrespective of age or stroke severity. Expand
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Among people with diabetes the proportional effects of statin therapy were similar irrespective of whether there was a prior history of vascular disease and irrespective of other baseline characteristics and should be considered for all diabetic individuals who are at sufficiently high risk of vascular events. Expand
Premature cardiovascular disease in chronic renal failure
If safe and effective treatments can be identified, and started early in the natural history of renal failure, the exceptionally high risk of CVD experienced by patients with chronic renal failure could be decreased before and after end-stage renal failure has occurred. Expand
Interpretation of the evidence for the efficacy and safety of statin therapy
The large-scale evidence from randomised trials indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery, and any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. Expand
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making. Expand